About Moderna, Inc. (MRNA)

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

MRNA Key Statistics

MRNA Price Performance

Moderna, Inc. stock has returned -6.87% over the past day, +4.10% over the past week, +34.21% over the past month, and +35.93% over the past three months. The stock trades between a 52-week low of $22.28 and a high of $59.55.

MRNA Financial Fundamentals

Moderna, Inc. reports a return on equity (ROE) of -28.87%, operating margin of -158.13%, profit margin of -14516.46%, and revenue growth of -29.80%. The debt-to-equity ratio is 0.15. Current ratio stands at 3.29.

MRNA Earnings

Moderna, Inc.'s next earnings report is expected on 2026-04-30 (56 days away). The company has a +1.00% earnings beat rate with an average surprise of +37.20%. Earnings consistency is rated as "high".

MRNA Ownership

Institutional investors hold approximately +0.77% of MRNA shares across 10 institutions. Insider ownership is +0.07%. Insider sentiment is "bearish".

MRNA Short Interest

MRNA has a short interest of +32.25% of float with a short ratio (days to cover) of 1.4.

MRNA AI Analysis Signal

iGotFomo's AI-powered signal engine rates MRNA as "HOLD" with MEDIUM confidence (score: 43/100). 5 signals are bullish, 5 are bearish, and 2 are neutral.